ESR1 and osteosarcoma: Our study found that the core genes of QGD in the treatment of osteosarcoma were TP53, SRC, and ESR1, and molecular docking revealed that the binding capacity of the core gene to its regulated compounds was lower than -5 kcal/mol, suggesting that QGD could be multitargeted for osteosarcoma.